Appointed
Christopher A. Marlett
Chairman of the Board
EXOZ ·
EXOZYMES INC.
The Board also appointed Mr. Christopher A. Marlett as the Chairman of the Board on the same date.
Ready 8-Ks
17
Latest filing
June 8, 2026, 2:19 PM ET
Top materiality
0.75
Event mix
other_material ×13 · other ×2 · leadership ×2
Sentiment
4 pos · 0 neg · 13 neu
Executive change
recent →
Recent 8-K filings for EXOZ
Highest-materiality recent filing
Invizyne completes $15M IPO; shares begin trading on Nasdaq under IZTC
- Priced 1,875,000 shares at $8.00; gross proceeds $15M, net proceeds ~$14.3M.
- Concurrent private placement issued 93,750 warrants at $0.125, exercisable at $8.00 for 5 years.
-
eXoZymes prices $5.33M offering of common stock and warrants at $18/unit
Sold 592,270 shares and 296,135 warrants as units at $18.00; gross proceeds ~$5.33M.
-
eXoZymes files 8-K with investor presentation for proposed public offering
Company disclosed it is pursuing a proposed public offering of securities; no specific terms provided in the filing.
-
eXoZymes shares investor presentation for proposed securities offering (April 10, 2026)
Presentation provided to potential underwriters and offering participants for a proposed securities offering.
-
eXoZymes files updated investor presentation for NCTx business; no details provided
eXoZymes furnished an updated Investor Presentation dated March 30, 2026 for its NCTx business.
-
eXoZymes reports 535g NCT pilot run at 99% conversion, 90% yield, 99.6% purity
Achieved ~99% reaction conversion, 90% isolated yield, and 535 g of NCT at 99.6% pharma-grade purity from a 100L pilot run.
-
eXoZymes achieves 100× scale-up of NCT production with >99% feedstock conversion
Scaled NCT production 100-fold using proprietary exozyme cell-free platform, achieving >99% conversion from feedstock to product.
-
ExoZymes files updated investor presentation for NCTx business; no specific financial data disclosed
eXoZymes issued an updated investor presentation dated November 13, 2025, focusing on its NCTx business.
-
ExoZymes files updated investor presentation as of September 30, 2025
Investor presentation filed as Exhibit 99.1 to Form 8-K on October 3, 2025
-
All six director nominees (Marlett, DiGiandomenico, Bowie, Lalonde, Bell, Rayo) elected with at least 4.25M votes for.
-
eXoZymes files updated Investor Presentation; no material disclosures in filing
Filing contains only a reference to an updated Investor Presentation as Exhibit 99.1.
-
eXoZymes to receive $3M from NSF as key partner in $9.2M cell-free biomanufacturing initiative
Selected as core industrial partner in Meta-PURE, a $9.2M NSF-funded project under CFIRE program.
-
eXoZymes increases CEO base salary to $450K, grants options and $250K bonus
CEO Michael Heltzen base salary raised to $450,000 annualized.
-
eXoZymes appoints Damien Perriman as CCO to lead commercial growth
Damien Perriman appointed to newly created CCO role, effective April 2, 2025.
-
eXoZymes provides Q4/FY2024 operational update; pre-revenue, advancing AI and commercialization
Completed IPO on Nasdaq on Nov 13, 2024; trades as EXOZ.
-
eXoZymes President and Chairman Mohammad Hayat resigns; Rayo, Marlett appointed
Mohammad Hayat resigned as director, President, and Chairman of eXoZymes Board on February 17, 2025.
-
Invizyne Technologies renamed eXoZymes Inc. effective Feb 10, 2025
Name changed from Invizyne Technologies Inc. to eXoZymes Inc. via certificate of amendment filed Feb 10, 2025.
-
Invizyne completes $15M IPO; shares begin trading on Nasdaq under IZTC
Priced 1,875,000 shares at $8.00; gross proceeds $15M, net proceeds ~$14.3M.
Executive changes
Departed
Mohammad Hayat
President and Chairman
EXOZ ·
EXOZYMES INC.
On February 17, 2025, Mr. Mohammad Hayat, a member of the Board of Directors (the “ Board ”) of eXoZymes Inc., a Nevada corporation (the “ Company ”), as well as its President and Chairman of the Board, resigned from the Board and from all positions he held in the Company.
Appointed
Edgardo Rayo
member of the Board
EXOZ ·
EXOZYMES INC.
On February 17, 2025, the Board appointed Mr. Edgardo Rayo as a member of the Board to fill the vacancy created by Mr. Hayat’s resignation.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.50 · Most common event other_material